The road ahead

‘The future will undoubtedly see wider and deeper scanning capabilities as well as faster spectrometers capable of more A scans per second, minimising motion artefacts, and the possibilities of portability are not far off,’ says Tim Baker, group CEO of Optopol distributor BIB Group Holdings. ‘Further improvements in general imaging quality, better take up in primary care utilising angiography within the general screening offering will all lead to earlier intervention and improved patient outcomes,’ he adds.

Claire Martin, Zeiss business development manager for retina and glaucoma, says: ‘Since its development, OCT technology has been an ever-evolving technology – now with macula, glaucoma and anterior segment modules, along with OCT angiography (OCT-A), which was developed more recently.’ As a foundation organisation, Zeiss continues to invest heavily in research and development to enhance patient care. ‘The evolution of OCT technology is set to continue, with a strong focus on improving digitalisation for shared care and maximising the possibilities of artificial intelligence,’ Martin adds.